Iranian patients face sharply higher prices for medicines and, in some cases, difficulty finding specific treatments, as US-related measures and sanctions pressure the country’s pharmaceutical sector.
Several outlets attribute the situation to a combination of a US blockade and stepped-up sanctions that limit the import, procurement, and production of medicines and related inputs. As supply becomes tighter, families report having to scramble for alternatives and pay more to obtain therapies.
Across the coverage, the core emphasis is on the impact on affordability and availability. While outlets vary slightly in phrasing—some focus more on the supply squeeze and others on the pricing surge—each describes a worsening environment for pharmaceutical access in Iran tied to sanctions and restrictions affecting medicine supply chains.